Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial

Keyphrases

• Anticoagulated Patients 7%
• Anticoagulation 7%
• Antiplatelet 7%
• Antiplatelet Therapy 100%
• Associated Risk 7%
• Bleeding Risk 7%
• Cardiac Implantable Electronic Device 23%
• Cardiac Rhythm Devices 100%
• Clinically Significant 30%
• Confidence Interval 7%
• Coumadin 7%
• Current Analysis 7%
• Device Implantation 100%
• Hematoma 30%
• Heparin Bridging 7%
• Oral Anticoagulation 7%
• Potentially Inappropriate 15%
• Randomized Controlled Trial 7%
• Relative Risk 7%
• Risk Prediction 7%
• Significant Risk Factors 7%
• Thromboembolism 7%
• Trial Registration 7%
• Warfarin 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiplatelet 100%
• Hematoma 28%
• Heparin 7%
• Randomized Controlled Trial 7%
• Thromboembolism 7%
• Warfarin 100%